Company (Symbol)* | University/Non-Profit [Scientist] | Type Of Agreement | Product Area | Details (Month) |
Affymetrix Inc. (AFFX) | The National Institutes of Health and the Wellcome Trust | Consortium agreement | To speed up the determination of the mouse genome sequence | Affymetrix will work, along with SmithKline Beecham, the Merck Genome Research Institute, the Wellcome Trust and six of the national institutes, to sequence the mouse genome (10/6) |
Affymetrix Inc. (AFFX) | Cystic Fibrosis Foundation | Development agreement | GeneChip expression array | Parties will develop a custom GeneChip expression array based on the Pseudomonas aeruginosa genome (8/31) |
Alteon Inc. (AMEX:ALT) and HemoMax LLC* | University of Pittsburgh's McGowan Center for Artificial Organ Development | Development agreement | Resuscitative fluid, HemoMax | Alteon will manage the preclinical development of compounds arising from the technology in return for a 15% ownership of HemoMax and the right of first negotiation to sublicense the technology later (10/10) |
Amersham Pharmacia Biotech (jointly owned by Nycomed Amersham plc [UK; NYSE:NYE] and Pharmacia Corp. [NYSE:PHA]) | Riken (The Institute of Physical and Chemical Research) [Yusuke Nakamura, Tokyo University] | Collaboration agreement | SNiPer SNP analysis system | Amersham signed an agreement with Riken to provide SNiPer SNP (single nucleotide polymorphism) analysis system to Riken and Japan's leading genetic researcher, Yusuke Nakamura (10/26) |
Antex Biologics Inc. (AMEX:ANX) | University of Maryland, College Park [J. Norman Hansen, Univ. of Maryland] | Worldwide, exclusive license agreement | Antibiotic peptides | Agreement is to develop and market new antibiotic peptides to conquer antibiotic-resistant bacteria; Antex will be responsible for preclinical and clinical development, and the university will receive royalty payments following commercialization (10/25) |
Antex Biologics Inc. (AMEX:ANX) | United States Department of the Navy | Cooperative Research and Development Agreement | Campyvax | The Navy will continue the clinical development of Campvax, a vaccine for the prevention of gastroenteritis, diarrhea and travelers' disease caused by Campylobacter; Antex will supply the vaccine and R&D support and the Navy will fund and conduct clinical trials through Phase III; Antex holds all intellectual property and marketing rights (8/16) |
AntexPharma (subsidiary of Antex Biologics Inc.; AMEX:ANX) | University of Maryland, Baltimore [K. Chul Kim] | Development and license agreement | Peptides | AntexPharma obtained exclusive worldwide rights to peptides that suppress the overproduction of mucus caused by many lung diseases (9/19) |
Antisoma plc (UK; LSE:ASM; EASD:ASOM) | German Cancer Research Centre | Licensing agreement | Anticancer agent | Antisoma in-licensed Thioplatin, a tumor-targeting agent; terms were ND (10/30) |
Ardais Corp.* | Duke University Medical Center and the Beth Israel Deaconess Medical Center | Alliance | Clinical genomics | Parties launched a nationwide initiative to collect, process and use high-quality clinical materials and the information associated with them (9/1) |
Aurora Biosciences Corp. (ABSC) | Hereditary Disease Foundation [Ethan Signer] | Alliance | Aurora's green fluorescent protein technology | Aurora will employ its green fluorescent protein technology and beta-lactamase reporter technology to develop cell-based and biochemical screening assays and to advance the discovery of new medicines to treat Huntington's disease (9/12) |
BioSignal Packard Inc. (unit of Packard BioScience Co.; PBSC) | University of Montreal | Collaboration agreement | Mammalian cell-based assays | BioSignal and the university will use the Bioluminescence Resonance Energy Transfer proteomics technology to develop the assays for the functional analysis of orphan G protein-coupled receptors (8/31) |
Boston Biomedica Inc. (BBII) | Consortium for Plasma Science LLC [Frederick Dombrose] | Extension of a collaborative agreement | Pressure cycling technology (PCT) | The extension of the December 1999 agreement allows BBI scientists to continue their research aimed at assessing PCT's ability to retain fragile plasma proteins, while inactivating viruses, such as HIV, hepatitis A, B and C, and Parvovirus B19 (9/21) |
Celera Genomics (NYSE:CRA) | Weizmann Institute of Science (Israel), California Institute of Technology, and The Institute of Genomic Research | Multiyear subscription agreement | Celera database products | Subscribers will access Celera's database information through its Celera Discovery System; financial terms were ND (10/18) |
Cel-Sci Corp. (AMEX:CVM) | Naval Medical Research Center | Extended cooperative research and development agreement | Malaria vaccine | Parties extended the CRADA to develop a malaria vaccine using Cel-Sci's LEAPS technology (9/5) |
Collateral Therapeutics (CLTX) | University of Texas Southwestern Medical Center | Research and license agreement | Gene discovery | Collateral exclusively licensed certain human genes and plans to commercialize the research and technology discovered to support the development of nonsurgical gene therapy products designed to improve heart muscle function (9/12) |
Copharos Inc.* | Mayo Clinic and the University of Minnesota | Licensing agreement | Vitamin B12-based imaging and therapeutic agents | The clinic and university collaborated to form Copharos, whose mission will be to direct the commercial development of the agents to be used in the early detection and treatment of lung, breast and other cancers (9/19) |
Corning Inc. (NYSE:GLW) | Whitehead Institute for Biomedical Research | Comprehensive research agreement | Life science research tools | Corning, which recently entered the DNA microarray market, entered an agreement to develop tools for life science research, such as gene expression analysis tools (10/25) |
Coulter Pharmaceutical Inc. (CLTR) | Yissum, the technology transfer company of Hebrew University | License and research agreement | Technology and property related to an approach to treat rheumatoid arthritis | Coulter acquired exclusive worldwide rights to the variant CD44 invention and will become the license holder of all technology and products developed; it has committed a two-year research grant, as well as milestones and royalties (10/2) |
Cybergenetics Inc.* | U.S. Department of Justice | Research contract | Validating automated forensic DNA analysis technology | Cybergenetics will use True-Allele to help reduce the national criminal offender DNA database backlog (10/5) |
Cytoclonal Pharmaceutics Inc. (CYPH) | Research & Development Institute at Montana State University | Rights agreement | Telomerase Reverse Transcriptase gene technology | Cytoclonal has exclusive rights to the technology and a corresponding fungal production system that makes telomerase, which is expressed in most human cancers (9/6) |
Diversa Corp. (DVSA) | Department of Energy's Idaho National Engineering and Environmental Laboratory | Biodiversity access agreement | Rights to environmental samples from Russia | Diversa gains the rights to discover genes from these samples and to commercialize resulting products in multiple markets (11/14) |
EluSys Therapeutics Inc.* | U.S. Army Medical Research Institute of Infectious Diseases | Collaboration | To develop treatments for anthrax and other potential biowarfare agents | They will develop antibodies to principal anthrax toxins that will be incorporated in EluSys' Heteropolymer technology (9/27) |
Enchira Biotechnology Corp. (ENBC) | The University of Texas M.D. Anderson Cancer Center | Research collaboration | To develop ligands that block the activation of epidermal growth factor receptors | Enchira will use its directed evolution platform to create ligands to prevent growth signaling at selective target tissues (10/10) |
Epimmune Inc. (EPMN) | Naval Medical Research Center Malaria Program | Collaboration | To apply its functional genomics technology, ImmunoSense, to the malaria parasite's genome | ImmunoSense will be used to identify antigens (immunogenic proteins) from raw genomic data to formulate a vaccine against malaria (9/28) |
Galenica Pharmaceuticals Inc.* | Naval Medical Research Center | Cooperative research and development agreement | Immunomodulator technology to develop a malaria vaccine | Galenica's lead candidate, GPI-0100, will be evaluated for its effectiveness in vaccine formulations containing antigens derived from the malaria parasite (10/31) |
Genome Therapeutics Corp. (GENE) | Ohio State University Research Foundation | Exclusive access agreement | Antimicrobial compounds | Genome gains a six-month exclusive option to obtain an exclusive license to patents relating to anti-infectives; the option may be extended for an additional six months (9/6) |
Genomics One Corp. (MSE:GNX) | National Research Council of Canada and Health Canada | Contract | To construct a True-Blue bacterial artificial chromosome library of Staphylococcus aureus | Financial terms were ND (9/26) |
ICOS Corp. (ICOS) | Stanford University [Arthur Kornberg] | Exclusive license agreement | Polyphosphate kinase technology | ICOS entered an exclusive license agreement with Stanford (11/13) |
Immtech International Inc. (IMMT) | Institute for Tuberculosis Research at the University of Illinois at Chicago [Scott Franzblau] | Collaborative research program | Therapeutic for drug-resistant Mycobacterium tuberculosis | The initial phase of the program will determine the ability of dicationic compounds to kill or inhibit TB residing with macrophages (9/21) |
Interleukin Genetics Inc. (ILGN) | Brigham and Women's Hospital | Collaboration | To investigate the genetic control of inflammation | Interleukin will use the Inflammatory Response Induction System to evaluate inflammatory responses in humans with specific IL-1 genetic variations (11/9) |
IMI International Medical Innovations Inc. (Canada; CDNX:IMIN) | McMaster University's Faculty of Health Sciences | Collaborative research agreement | Research projects for early-stage cancer detection | IMI will sponsor research using genomics for early-stage cancer detection; IMI has right of first refusal for technologies generated by the $750,000 collaboration (11/8) |
Isis Pharmaceuticals Inc. (ISIP) | Alliance for Cellular Signaling | Alliance | Understanding cells | Isis' GeneTrove genomics division will provide its expertise in creating and using antisense inhibitors to identify the function of genes and the role they play in cellular interactions, or pathways (9/5) |
Kos Pharmaceuticals Inc. (KOSP) | Purdue Research Foundation (division of Purdue University) | Exclusive commercial agreement | Gastric retention drug delivery system | Kos will use the delivery method to develop once-daily formulations of currently marketed pharmaceuticals that now require multiple doses due to poor absorption; agreement includes undisclosed milestone payments and royalty payments based on future products (10/29) |
Lexicon Genetics Inc. (LEXG) | Merck Genome Research Institute | Conclusion of collaboration | Production of the OmniBank library | MGRI paid Lexicon $4M upfront and will make a final cash payment of $1M; the parties developed Lexicon's gene trapping process for the production of its OmniBank library of knockout mouse clones for functional genomics research (9/29) |
Lynx Therapeutics (LYNX) | Institute of Molecular and Cell Biology (affiliated with the National University of Singapore [Y.H. Tan]) | Collaboration | To discover genes and molecular mechanisms involved in cancer, infectious diseases and other diseases prevalent in Asia Pacific | Lynx will apply its Megasort and Massively Parallel Signature Sequencing technologies to samples provided by the IMCB; Lynx will receive payments for technology access fees and genomics discovery services; the parties will jointly own the results, but one of the two will commercialize them, sharing the financial benefits (10/31) |
Medicure Inc. (Canada; CDNX:MPH) | George Washington University | License agreement | Three cardiovascular therapeutics | Medicure agreed to acquire the therapeutics and will evaluate and license them; Medicure also will acquire exclusive worldwide rights to the technology in exchange for royalties and other commercialization-contingent payments (11/3) |
MitoKor* | University of California, San Diego | Research collaboration | Novel treatments for osteoarthritis | A grant from BioSTAR (biotechnology strategic targets for research) will fund the collaboration; initial studies will focus on whether therapeutic protection of mitochondria can preserve the function of cells in the cartilage of joints (10/24) |
Myriad Genetics Inc. (MYGN) | Alliance for Cellular Signaling | Alliance | ProNet technology | Myriad will use its ProNet technology to discover the means by which cells communicate (9/5) |
Nanogen Inc. (NGEN) | The Children's Hospital of Philadelphia [Paolo Fortina] | Collaboration | High-accuracy genetic tests | The object is to accelerate development of clinical diagnostics assays on Nanogen's DNA microchips; Children's Hospital will provide laboratory resources, expertise and product revenue in exchange for nonexclusive access to Nanogen's DNA micrarray technology (10/31) |
Nanogen Inc. (NGEN) | U.S. Army Medical Research Acquisition Activity | Cooperative agreement | To develop an arrayable electronic system for the identification of biological warfare or infectious disease agents | Nanogen will complete and deliver devices and protocols for performing a nucleic acid amplification and hybridization approach; agreement totals $1.1M over the next two years (10/5) |
Novavax Inc. (AMEX:NOX) and Science Applications International Corp. | National Institute of Allergy and Infectious Diseases [Robin Robinson, Novavax] | Seven-year subcontract | Malaria vaccine production and support services | SAIC assembled a team that includes Novavax for a contract awarded by NIAID; Novavax will evaluate the process of developing malaria protein vaccine candidates using multiple expression systems, as well as bacterial and viral vectors; it also will be responsbile for process development and GMP manufacturing and testing of the candidates; the subcontract is estimated to be valued at $10.5M (10/19) |
OraVax Inc. (subsidiary of Peptide Therapeutics Group plc; LSE:PTE) | Centers for Disease Control and Prevention | 20-year development and manufacturing agreement | Smallpox vaccine | The contract is valued at $343M; OraVax will have the exclusive commercial rights to the vaccine developed (9/20) |
Orchid BioSciences Inc. (ORCH) | City of New York | Contract | To screen criminal evidence and generate DNA samples | Orchid will screen the evidence and New York's chief medical examiner staff will compare DNA to local, state and federal criminal databases to help identify the perpetrators of serious crimes (9/27) |
Oxxon Pharmaccines Ltd.* (UK) | Imperial College Innovations Ltd. [Adrian Hill; Oxford University] | Licensing agreement | Vaccines to treat chronic infectious diseases and cancer | The license covers the worldwide use of TRAP DNA in Oxxon's Prime Boost Technologies to treat or prevent malaria in humans (9/7) |
Pharsight Corp. (PHST) | Duke University Medical Center | Master Sponsored Research Agreement | Multiple therapeutic areas | Agreement allows Pharsight to license data across multiple therapeutic areas, with near-term focus on cardiovascular, central nervous system and psychiatric drug therapies (10/26) |
PPGx Inc.* | Bioinformatics Research Center at North Carolina State University | One-year renewable partnership | Interpretation of pharmacogenomic data | Researchers will develop and implement statistical methodologies to speed and enhance the analysis and interpretation of pharmacogenomic data (8/30) |
SignalGene (TSE:SGI) | Universite Laval and the Centre Hospitalier Affilie Universitaire de Quebec | Scientific collaboration agreement | Identification of genetic risk factors involved in breast cancer | The agreement creates a partnership between SignalGene scientists and the university's research team (10/16) |
Syn X Pharma Inc. (Canada; CDNX:SYY) | University of Liege, Belgium [Michel Georges] | Agreement to acquire rights | Patent for a method for determining the presence of muscular hyperplasia in a mammal | Syn X has an ongoing agreement with the university to fund basic research on myostatin, including exclusive rights to commercialize potential applications of that research (8/31) |
The Institute for Genomic Research | Universities of California, Minnesota, Wisconsin and Cornell | Collaboration | Potato functional genomics | TIGR will generate 60,000 ESTs from various potato cDNA libraries (10/11) |
The Institute for Genomic Research | National, Heart, Lung and Blood Institute [John Quackenbush; TIGR] | Consortium agreement | To establish 11 four-year Programs for Genomic Applications | The programs will use and expand on data and technologies to advance genomic research related to heart, lung, blood and sleep disorders (10/10) |
Viragen Ltd. (Scotland; unit of Viragen Inc. [AMEX:VRA]) | Memorial SloanKettering Cancer Center | Production collaboration | To produce human monoclonal antibodies to treat melanoma and other cancers | Viragen's antibodies will be delivered to Memorial Sloan's laboratories for in vitro experiments; Viragen expects to deliver the first antibody in the first quarter of 2001 (10/17) |
Viragen Inc. (AMEX:VRA) | National Institutes of Health | Licensing agreement | Monoclonal antibody or antibody fragment protein and that recognizes Notch-1 pharmaceutical compositions | Viragen gained exclusive rights to the use of the antibody to treat tumors that overexpress Notch-1 protein (9/27) |
Viragen Inc. (AMEX:VRA) | UK's Cancer Research Campaign Technology | Development license agreement | Technology relating to a tumor-associated antigen and a method for its isolation and use in cancer vaccines and other treatments | Viragen gained worldwide exclusive commercial rights to develop, research, use, make and sell the technology (9/7) |
Notes: |
||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. |
||||
AMEX = American Stock Exchange; CDNX = Canadian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-The-Counter Bulletin Board; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange |
||||
Unless otherwise noted, the stock symbols listed are on the Nasdaq market. |
||||
* Privately held company |
||||
ND = Not disclosed. |
||||